Back to search results

EBV-specific Cytotoxic T-lymphocytes for Refractory EBV Infection

This study is testing a treatment called EBV-specific cytotoxic T-lymphocytes (CTLs) for people with Epstein-Barr Virus (EBV) infections that haven't responded to other treatments. These special immune cells are made from a related donor and are designed to fight the EBV infection. You might be able to join if you are between 1 month and 79 years old and have an EBV infection after a stem cell transplant, with a primary immune deficiency, or after an organ transplant. The study is looking at how safe the treatment is and if it helps reduce the infection. The current status of this study is unclear, and it plans to enroll 20 participants.

Study design
This is an interventional study with an unclear phase, planning to enroll 20 participants.
What's involved
You will receive infusions of EBV specific CTLs and be followed for 12 weeks after each infusion to check for side effects and treatment response.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for 12 weeks after each infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03266653

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Recruiting
PHASE2Ages 1–79InterventionalTreatment
New York Medical College
~20 participants
Updated 2025-08-08 on ClinicalTrials.gov
What's tested:cytotoxic t-lymphocytes

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Measured over Patients will be followed for 12 weeks after each infusion
+1 more outcome measured

Conditions

Epstein-Barr Virus Infections
Primary Immune Deficiency Disorder

Explore related trials

EBV InfectionInborn Error of Immunity

Where it's being run

8 sites across 7 states
California2
Maryland1
Missouri1
New York1
Ohio1
Pennsylvania1
Wisconsin1

Study leadership

  • Mitchell Cairo, MD · PRINCIPAL_INVESTIGATOR · New York Medical College

Who to contact

Mitchell Cairo, MD
[email protected]
914-594-2150
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Patients will be followed for 12 weeks after each infusion

    Patients will be monitored for adverse events related to the infusion of EBV CTLs

  • Incidence of Response to Treatment [Efficacy]Patients will be followed for 12 weeks after each infusion

    Patients will be followed for improvement in viral infection by monitoring EBV PCR weekly for response to treatment with CTLs